Skip to main content

Diabetes Drug News

Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.

Metformin     Insulin     SGLT-2     GLP-1     DPP-4     Combo drugs     Sulfonylureas     TZDs

Clinical trial participants taking retatrutide for obesity experienced an average of 24% in body weight reduction over 48 weeks. Lead scientists shared their findings at...
PIONEER PLUS and OASIS 1 trials show high-dose Rybelsus significantly reduces A1C and promotes weight loss in type 2 diabetes and obesity patients.
Clinical trial results have shown that once-weekly basal insulins are just as effective at reducing A1C as once-daily insulin.
Results from a recent clinical trial showed the new medication survodutide may be a useful treatment tool for weight loss. People with overweight or obesity on the...
end Uncover SURMOUNT-2 trial's outcomes: Tirzepatide's promise for weight loss, better blood sugar, and improved cardiometabolic health in type 2 diabetes.
New drug treatments are now available for children with diabetes following the recent approval of Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin...
Join diaTribe at the American Diabetes Association's 83rd scientific conference for insights on future diabetes care, medication, and the latest tech. Plus, explore...
Understand the stigma linked to medication use for diabetes and obesity management. Let's change the perception and enhance our healthcare conversations.
SGLT-2 inhibitors can protect your heart! This type of medicine is recommended for people with type 2 diabetes who have heart disease or risk factors related to heart...
FDA warns people to avoid using some forms of compounded substitutes of semaglutides that lack the safety and efficacy of popular weight loss drugs Wegovy, Ozempic, and...
Reduce heart failure risk with FDA-approved Inpefa (sotagliflozin). Inhibiting SGLT-2 and SGLT-1, it outshines other medications. Learn more about its effectiveness and...
In case you missed them, here are our top stories from May 2023. This month’s best stories cover a wide variety of topics like upcoming therapies, new research findings...
Oculis' OCS-01 eye drops show promising results in phase 3 trials for diabetic macular edema treatment. Uncover a potential revolution in non-invasive eye care solutions.
Early findings from a phase 3 clinical trial demonstrated that participants treated with 50 mg oral semaglutide achieved a remarkable weight loss of 17.4%. This research...
Farxiga (dapagliflozin), a SGLT-2 inhibitor, has officially been approved by the FDA to treat all types of heart failure, a common diabetes complication.
The FDA has cleared the Omnipod GO: a discreet, water-resistant insulin pod with up to 3 days of wear. Enjoy the freedom and convenience to manage your diabetes.
The FDA recently cleared a new experimental drug for type 1 diabetes to begin a phase 2 clinical trial. If approved, the drug would be the first therapy to specifically...
Researchers released clinical trial data on a new treatment for type 2 diabetes that may help the body’s insulin-producing cells regenerate. 78% of the clinical trial’s...
Mark Cuban’s Cost Plus Drug Company recently added SGLT-2 inhibitor Invokana to its list of available medications. The company, which uses an innovative business model...
California Gov. Gavin Newsom announced a $50-million contract with Civica Rx to produce the state’s own insulin, adding to the recent new policies aiming to make this...

Pages